» Articles » PMID: 35361921

DNA Methylation Signature Associated with Bohring-Opitz Syndrome: a New Tool for Functional Classification of Variants in ASXL Genes

Abstract

The additional sex combs-like (ASXL) gene family-encoded by ASXL1, ASXL2, and ASXL3-is crucial for mammalian development. Pathogenic variants in the ASXL gene family are associated with three phenotypically distinct neurodevelopmental syndromes. Our previous work has shown that syndromic conditions caused by pathogenic variants in epigenetic regulatory genes show consistent patterns of genome-wide DNA methylation (DNAm) alterations, i.e., DNAm signatures in peripheral blood. Given the role of ASXL1 in chromatin modification, we hypothesized that pathogenic ASXL1 variants underlying Bohring-Opitz syndrome (BOS) have a unique DNAm signature. We profiled whole-blood DNAm for 17 ASXL1 variants, and 35 sex- and age-matched typically developing individuals, using Illumina's Infinium EPIC array. We identified 763 differentially methylated CpG sites in individuals with BOS. Differentially methylated sites overlapped 323 unique genes, including HOXA5 and HOXB4, supporting the functional relevance of DNAm signatures. We used a machine-learning classification model based on the BOS DNAm signature to classify variants of uncertain significance in ASXL1, as well as pathogenic ASXL2 and ASXL3 variants. The DNAm profile of one individual with the ASXL2 variant was BOS-like, whereas the DNAm profiles of three individuals with ASXL3 variants were control-like. We also used Horvath's epigenetic clock, which showed acceleration in DNAm age in individuals with pathogenic ASXL1 variants, and the individual with the pathogenic ASXL2 variant, but not in individuals with ASXL3 variants. These studies enhance our understanding of the epigenetic dysregulation underpinning ASXL gene family-associated syndromes.

Citing Articles

Polycomb-associated and Trithorax-associated developmental conditions-phenotypic convergence and heterogeneity.

Smail A, Al-Jawahiri R, Baker K Eur J Hum Genet. 2025; .

PMID: 39843918 DOI: 10.1038/s41431-025-01784-2.


ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3.

Lin I, Awamleh Z, Sinvhal M, Wan A, Bondhus L, Wei A BMC Med Genomics. 2024; 17(1):282.

PMID: 39614348 PMC: 11606099. DOI: 10.1186/s12920-024-02039-7.


A new blood DNA methylation signature for Koolen-de Vries syndrome: Classification of missense KANSL1 variants and comparison to fibroblast cells.

Awamleh Z, Choufani S, Wu W, Rots D, Dingemans A, Nadif Kasri N Eur J Hum Genet. 2024; 32(3):324-332.

PMID: 38282074 PMC: 10923882. DOI: 10.1038/s41431-024-01538-6.


Chromatinopathies: insight in clinical aspects and underlying epigenetic changes.

Bukowska-Olech E, Majchrzak-Celinska A, Przyborska M, Jamsheer A J Appl Genet. 2024; 65(2):287-301.

PMID: 38180712 PMC: 11003913. DOI: 10.1007/s13353-023-00824-1.


KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster.

Singh M, Spendlove S, Wei A, Bondhus L, Nava A, de L Vitorino F Hum Genet. 2023; 142(12):1705-1720.

PMID: 37861717 PMC: 10676314. DOI: 10.1007/s00439-023-02608-3.


References
1.
Katoh M . Functional and cancer genomics of ASXL family members. Br J Cancer. 2013; 109(2):299-306. PMC: 3721406. DOI: 10.1038/bjc.2013.281. View

2.
Cuddapah V, Dubbs H, Adang L, Kugler S, McCormick E, Zolkipli-Cunningham Z . Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature. Am J Med Genet A. 2021; 185(6):1700-1711. PMC: 8842511. DOI: 10.1002/ajmg.a.62156. View

3.
Hoischen A, van Bon B, Rodriguez-Santiago B, Gilissen C, Vissers L, De Vries P . De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet. 2011; 43(8):729-31. DOI: 10.1038/ng.868. View

4.
Russell B, Johnston J, Biesecker L, Kramer N, Pickart A, Rhead W . Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. Am J Med Genet A. 2015; 167A(9):2122-31. PMC: 4760347. DOI: 10.1002/ajmg.a.37131. View

5.
Bainbridge M, Hu H, Muzny D, Musante L, Lupski J, Graham B . De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med. 2013; 5(2):11. PMC: 3707024. DOI: 10.1186/gm415. View